Caumette, Elsa http://orcid.org/0000-0001-9162-5476
Di Meglio, Antonio
Vaz-Luis, Inès
Charles, Cécile
Havas, Julie
de Azua, Garazi Ruiz
Martin, Elise
Vanlemmens, Laurence
Delaloge, Suzette
Everhard, Sibille
Martin, Anne-Laure
Merimeche, Asma Dhaini
Rigal, Olivier
Coutant, Charles
Fournier, Marion
Jouannaud, Christelle
Soulie, Patrick
Cottu, Paul-Henri
Tredan, Olivier
Menvielle, Gwenn
Dumas, Agnès
Funding for this research was provided by:
French Foundation for Cancer Research (Grant No. ARC, PGA1 RF20170205420)
Susan G. Komen Career Catalyst Research (Grant No. CCR17483507 to I.V.L)
ODYSSEA program
National Research Agency (Grant No. ANR-10-COHO0004)
University of Montpellier's Department of maieutics
Article History
Received: 20 January 2022
Accepted: 20 February 2022
First Online: 10 March 2022
Declarations
:
: The study was approved by the French regulatory authorities under reference B11158-20 (09/14/2011) and the French Ethics Committee Ile de France VII under reference 11–039 (10/14/2011).
: All the women were aged 18 or over at diagnosis and provided written informed consent.
: Elsa Caumette: no conflict of interest; Inès Vaz-Luis have personal financial interests: institutional support from Pfizer Amgen, AstraZeneca (Public Speaking); Cécile Charles: no conflict of interest; Julie Havas: no conflict of interest; Garazi Ruiz de Azua: no conflict of interest; Elise Martin: no conflict of interest; Antonio Di Meglio: no conflict of interest; Suzette Delaloge reports institutional consulting fees from AstraZeneca, Besins, Sanofi, Rappta; institutional honoraria from AstraZeneca, Seagen, MSD, Pfizer; institutional investigating fees from Taiho, AstraZeneca, Pfizer, MSD, Novartis, Sanofi, G1 therapeutics, BMS, Pfizer, Roche; and personal support for attending US conference from AstraZeneca and Pfizer; Olivier Rigal Honoraria: Pfizer, Seagen et Viatris; Charles Coutant: Honoraria: Roche, MSD, AstraZeneca, Seagen; Marion Fournier Symposium rémunéré Myriade genetics SFCO; Christelle Jouannaud Honoraria: Daiichi Sankyo, AstraZeneca, Pfizer; Travel/Accommodations/expenses: Novartis; Patrick Soulie no disclosure; Paul-Henri Cottu Honoraria: Pfizer, Roche, Lilly, Pierre Fabre, Institution honoraria: Novartis, NanoString Technologies; Consultant/Advisory Role: Pfizer, Roche/Genentech, Lilly; Research funding: Novartis, Pfizer; Travel/Accommodations/expenses: Pfizer, Roche; Olivier Tredan Grants: Roche, BMS, MSD-Merck, personal fees: Novartis-Sandoz, Pfizer, Lilly, AstraZeneca, Daiichi Sankyo, Eisai, Pierre Fabre, Seagen, Roche, MSD-Merck; Asma Dhaini Merimeche, Laurence Vanlemmens, Sibille Everhard, Anne-Laure Martin: NO DISCLOSURE; Gwenn Menvielle: no conflict of interest; Agnès Dumas: no conflict of interest.